While vemurafenib, dabrafenib, and encorafenib all belong to the class of BRAF inhibitors used to treat BRAF-mutated melanoma, the selection among them may hinge on various factors, including the patient’s specific mutation, treatment history, and individual tolerance to side effects. The gene discussed is BRAF; the disease is melanoma.